Press Release and presentation

Press Release - Q1FY27 - Revenue 2,229 Cr +17% y-y; EBITDA 268 Cr (margin 11.9%, -385 bps y-y); PAT 56 Cr (-45% y-y) - Broad-based revenue growth led by CDMO Sterile Injectables; EBITDA margins declined due to SPECT product unavailability and higher expenses - Commercial batch production for SPECT radiopharmaceuticals started; margins expected to improve from H2FY27 - Radiopharma revenue +19% with Ruby-Fill® installs up 26%; PET manufacturing expansion underway - CDMO Spokane Line 3 ramping up; Line 4 installation complete, production expected FY28 - CRDMO Drug Discovery revenue +8%, margins improved; API margins pressured by raw material costs - Generics revenue +4%, margin pressure due to product mix; multiple product launches planned - Proprietary Novel Drugs progressing clinical trials; data readouts expected CY26 - Net debt/EBITDA at 1.8x; capex guidance similar to FY26